Replies to post #17136 on RespireRx Pharmaceuticals Inc (fka RSPI)

[atheroprevent]

Neuro, did you note any R+R participation or presence?

I was impressed that the RD trials started patients within 72 hours after regulatory approval (even if incentivized).

I also liked the fact that the Huntingtons Foundation was excited enough about the ampakine effect in the animal model, that they wanted to test further on their own dime. This could translate to a higher regard for our discounted shares and possibly to some non traditional funding down the road.

[bladerunner1717]

Neuro,

Besides boilerplate references to "confidentiality" and such (and yes, SGP is in charge of the trials, blah, blah, blah), is there any reason that you can think of that COR never mentions verbally in these public forums anything having to do with the partnership with SGP? Specifically, one might have thought that Stoll would at least mention that SGP had taken a COR Ampakine into trials in ADHD. And, btw, it's hard for me to believe that SGP would take a COR Ampakine into ADHD without seeing something pretty promising in schizo and/or depression. Do you agree? Furthermore, doesn't it make sense that if SGP has really promising results in ADHD, they would want to lock up some rights to COR's later patent expiration low-impacts?


Bladerunner

[jerrydylan]

I still think the use patent in RD is huge. It may end up being incredibly valuable.

[gfp927z]

A few impressions on the SHM:
1) The transition to Mark Varney as CEO has always been the underlying plan--no one forced Stoll to do anything.The fact that they announced it now makes me think that there has been no hint of failure (that doesn't necessarily mean there is a hint of success) from Germany. If Varney thought the company was about to blow up, he might have demurred.

Well, I would.

2) The mood amongst Cortex management was positive, not ebullient. I don't think they know anything for sure yet. Pierre Tran had come back from Germany, and he made a joke at some point, and if anyone has a sense from watching the patients, he would.

3) Stoll actually did make reference to the share price and believing that it's very undervalued--not that I expected anything else, but it's not as if he didnt acknowledge the current situation. His presentation was as usual, which is in the midrange for execs. There are some who are flashy but sleazy, there are some who are totally boring, he's in neither group--but you have to have interest in the data he's showing. Spoonfeeding and cheerleading is not his style. There are just a few CEOs who stand out in their presenting, Don deBethizy of Targacept is one example. But the issue here is not presenter style--put deBethizy up there presenting the same pending binary scenario, and the stock will do exactly the same thing. Varney is also very lowkey--but I'm more interested in the fact he got Street and Tran to join up.

4) Other important points: CX1739 is not delayed, it's finishing its tox work, and they clearly expect it to be in the clinic 3Q.

I asked specifically whether anything had caused a caution flag on the first high impact, CX1837. There has not been, but it's still early in the tox testing process.

There is no use patent on ADHD, which accounts for SP going ahead without a license. Stoll made a half-hearted reference to the cognition patent perhaps applying, but he more importantly indicated that there is some prior art (must be vis-a-vis attention specifically) that prevented a use patent for ADHD. So Cortex's leverage there is strictly molecule-based.

NeuroInvestment